About ICM-403

ICM developing gene therapy for hearing loss is ICM-403 targeting Pendrin, which is the most common cause of congenital hearing loss in East Asian. Small-scale production for both pipelines has been completed, and the rout of administration (ROA) has been established for therapeutic vector delivery to cochlea by employing round-window injection (RWI). Pre-clinical studies of ICM-403 are being actively pursued in various hearing loss animal models. Pre-clinical studies of ICM-403 are being conducted in hearing loss animal models.